Coya Therapeutics (COYA)
Market Price (3/14/2026): $4.62 | Market Cap: $77.3 MilSector: Health Care | Industry: Biotechnology
Coya Therapeutics (COYA)
Market Price (3/14/2026): $4.62Market Cap: $77.3 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -37% | Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -73% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -517% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -92% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -58% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies. | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 100% | |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -304%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -304% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28% | ||
| Key risksCOYA key risks include [1] specific regulatory setbacks, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -37% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -92% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -84%, 3Y Excs Rtn is -73% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -21 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -517% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -58% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 100% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -304%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -304% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -28% |
| Key risksCOYA key risks include [1] specific regulatory setbacks, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Shareholder dilution from capital raises negatively impacted stock value. The company executed a private placement on January 30, 2026, issuing 2,522,727 shares of common stock at $4.40 per share, which generated approximately $11.1 million in gross proceeds but also contributed to substantial shareholder dilution. Overall, Coya Therapeutics experienced a 40.3% increase in total shares outstanding over the past year.
2. Persistent financial losses and a negative earnings outlook contributed to investor apprehension. Coya Therapeutics reported an earnings per share (EPS) of -$0.10 for Q3 2025, missing analyst consensus estimates by $0.12. Analysts project continued unprofitability, with an expected EPS loss of ($0.08) for Q4 2025 and a further decrease in earnings from ($1.15) to ($1.47) per share in the upcoming year.
Show more
Stock Movement Drivers
Fundamental Drivers
The -30.4% change in COYA stock from 11/30/2025 to 3/13/2026 was primarily driven by a -30.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.51 | 4.53 | -30.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 4 | 4 | 0.0% |
| P/S Multiple | 27.3 | 19.0 | -30.4% |
| Shares Outstanding (Mil) | 17 | 17 | 0.0% |
| Cumulative Contribution | -30.4% |
Market Drivers
11/30/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| COYA | -30.4% | |
| Market (SPY) | -3.1% | 21.3% |
| Sector (XLV) | -5.0% | 19.3% |
Fundamental Drivers
The -30.9% change in COYA stock from 8/31/2025 to 3/13/2026 was primarily driven by a -92.7% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 6.56 | 4.53 | -30.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 4 | 841.7% |
| P/S Multiple | 259.1 | 19.0 | -92.7% |
| Shares Outstanding (Mil) | 17 | 17 | 0.0% |
| Cumulative Contribution | -30.9% |
Market Drivers
8/31/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| COYA | -30.9% | |
| Market (SPY) | 3.0% | 12.1% |
| Sector (XLV) | 9.5% | 20.6% |
Fundamental Drivers
The -36.0% change in COYA stock from 2/28/2025 to 3/13/2026 was primarily driven by a -58.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 7.08 | 4.53 | -36.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 10 | 4 | -58.3% |
| P/S Multiple | 11.3 | 19.0 | 68.5% |
| Shares Outstanding (Mil) | 15 | 17 | -9.0% |
| Cumulative Contribution | -36.0% |
Market Drivers
2/28/2025 to 3/13/2026| Return | Correlation | |
|---|---|---|
| COYA | -36.0% | |
| Market (SPY) | 12.4% | 26.7% |
| Sector (XLV) | 1.9% | 32.1% |
Fundamental Drivers
The 10.8% change in COYA stock from 2/28/2023 to 3/13/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282023 | 3132026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.09 | 4.53 | 10.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 4 | 0.0% |
| P/S Multiple | � | 19.0 | 0.0% |
| Shares Outstanding (Mil) | 7 | 17 | -60.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/13/2026| Return | Correlation | |
|---|---|---|
| COYA | 10.8% | |
| Market (SPY) | 73.4% | 19.4% |
| Sector (XLV) | 23.3% | 20.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| COYA Return | - | 4% | 56% | -23% | 1% | -15% | 8% |
| Peers Return | -12% | 52% | 16% | -74% | 73% | 25% | -12% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 80% |
Monthly Win Rates [3] | |||||||
| COYA Win Rate | - | 100% | 42% | 42% | 67% | 33% | |
| Peers Win Rate | 53% | 42% | 44% | 29% | 57% | 67% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| COYA Max Drawdown | - | 0% | -30% | -35% | -14% | -31% | |
| Peers Max Drawdown | -28% | -59% | -42% | -78% | -41% | -9% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BIIB, AMLX, ALEC, KYTX, CABA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/13/2026 (YTD)
How Low Can It Go
| Event | COYA | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -43.4% | -25.4% |
| % Gain to Breakeven | 76.7% | 34.1% |
| Time to Breakeven | 58 days | 464 days |
Compare to BIIB, AMLX, ALEC, KYTX, CABA
In The Past
Coya Therapeutics's stock fell -43.4% during the 2022 Inflation Shock from a high on 5/16/2023. A -43.4% loss requires a 76.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Coya Therapeutics (COYA)
AI Analysis | Feedback
Like a Kite Pharma, but developing regulatory T-cell (Treg) therapies for neurodegenerative diseases like ALS, rather than CAR-T for cancer.
Imagine an immunology pioneer like Genentech, but exclusively dedicated to developing medicines that modulate regulatory T cells for conditions like dementia and autoimmune disorders.
Think of a specialized biotech like Vertex Pharmaceuticals, but instead of targeting genetic diseases, COYA focuses on precisely tuning regulatory T cells for neurodegenerative and autoimmune conditions.
AI Analysis | Feedback
- COYA 101: An autologous regulatory T-cell product candidate for treating Amyotrophic Lateral Sclerosis.
- COYA 301: A Treg-enhancing biologic for treating Frontotemporal Dementia.
- COYA 302: A biologic combination designed to enhance Treg function and deplete T effector cells for neurodegenerative and autoimmune diseases.
- COYA 201: An allogeneic Treg exosome product candidate for neurodegenerative, autoimmune, and metabolic diseases.
- COYA 206: An antigen-directed Treg-derived exosome product candidate in discovery stage.
AI Analysis | Feedback
Coya Therapeutics, Inc. (COYA) is a clinical-stage biotechnology company focused on developing medicinal products. As a clinical-stage company, its product candidates are currently in various stages of development, including clinical trials (Phase 2a), IND-enabling studies, preclinical stages, and discovery stages. At this stage, Coya Therapeutics does not have commercialized products for sale and therefore does not have major customers in the traditional sense of companies or individuals purchasing its products. Its operations are centered around research and development, and conducting clinical trials. Future customers, if its products are successfully developed and approved, would likely include healthcare providers, hospitals, and potentially pharmaceutical partners for commercialization.AI Analysis | Feedback
- Lonza Group AG (LONN.SW)
- Catalent, Inc. (CTLT)
- Emergent BioSolutions, Inc. (EBS)
- Parexel International Corporation
AI Analysis | Feedback
Arun Swaminathan, Ph.D. Chief Executive Officer
Dr. Arun Swaminathan became Coya Therapeutics' Chief Executive Officer on November 1, 2024, after joining the company as Chief Business Officer in April 2023 and being appointed to the Board in August 2024. He brings over 20 years of healthcare business executive experience with a strong focus on corporate and business development, strategy, and finance. Previously, Dr. Swaminathan co-founded and served as CEO of Lynkogen Inc., a pre-clinical stage biotech. He also held the role of Chief Business Officer for Actinium Pharmaceuticals, where he spearheaded a $452 million deal, and for Alteogen, where he led deals totaling over $6 billion. He began his career in clinical development and commercial roles at BristolMyers Squibb and Covance.
David S. Snyder, M.B.A. Chief Financial Officer and Chief Operating Officer
David S. Snyder joined Coya Therapeutics in March 2022 as Chief Financial Officer and Chief Operating Officer, bringing over 25 years of experience as CFO for public and high-growth companies. He has assisted four life science companies in preparing for public company operations. Prior to Coya, he served as CFO for DisperSol Technologies, LLC and its wholly-owned subsidiary Austhera BioSciences, Inc. His past CFO roles include Exicure, Inc. (2014-2020), Cellular Dynamics, Inc. (2008-2014), and Roche NimbleGen (2007-2008). Earlier in his career, Mr. Snyder was CFO for companies in the real estate, software, and manufacturing sectors, and worked with financial and real estate investor Sam Zell.
Howard Berman, Ph.D. Executive Chairman
Dr. Howard Berman co-founded Coya Therapeutics in 2020 and served as its Chief Executive Officer from inception until October 30, 2024, when he transitioned to his current role as Executive Chairman. He successfully guided Coya through its IPO in 2023. Dr. Berman is also the founder of Imaware, Inc., a company he successfully led through a strategic M&A acquisition in 2024. With over 25 years of leadership experience across both public and private life sciences companies, he previously held management and clinical development positions at leading global biopharmaceutical companies such as Novartis, Eli Lilly, AbbVie, and Morphosys, where he contributed to the development and launch of numerous drugs. He has raised over $100 million in venture, public, and non-dilutive funding.
Fred Grossman, Ph.D. President and Chief Medical Officer
Dr. Fred Grossman was appointed President and Chief Medical Officer of Coya Therapeutics in July 2023. He possesses extensive experience, having held executive positions at prominent pharmaceutical companies including Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Sunovion, Glenmark Pharmaceuticals, and Mesoblast Inc. At Glenmark Pharmaceuticals, he oversaw the development of the entire pipeline, encompassing generics, complex generics, and next-generation biologics. His experience also includes serving as Chief Medical Officer at Mesoblast, Inc., where he focused on developing allogeneic cellular therapies for inflammatory diseases.
AI Analysis | Feedback
Coya Therapeutics (COYA), a clinical-stage biotechnology company, faces several key risks inherent to its stage of development and its focus on novel therapeutic modalities. The most significant risks include:- Clinical Trial Failure and Drug Development Risk: As a clinical-stage company, Coya Therapeutics' success is heavily dependent on the successful outcome of its ongoing and planned clinical trials. Setbacks, delays, or outright failures in these trials due to lack of efficacy, safety concerns, or other issues could severely impact the company. Its product candidates, such as COYA 101, COYA 301, COYA 302, COYA 201, and COYA 206, are in various stages of development, from discovery to Phase 2a, meaning the path to commercialization is long and uncertain. The ability of these candidates to achieve applicable endpoints in clinical trials and demonstrate a favorable safety profile is critical for their advancement.
- Regulatory Approval Risk: Even with successful clinical trial results, Coya Therapeutics must obtain regulatory approval from agencies such as the FDA to market its products. There is no guarantee that regulatory bodies will approve the company's product candidates, a fundamental hurdle for any clinical-stage biopharmaceutical company with no products approved for commercial sale. The timing and eventual outcome of these regulatory reviews are significant uncertainties.
- Funding and Capital Risk: Developing novel therapeutics is a capital-intensive process. Coya Therapeutics has reported net losses and an accumulated deficit, indicating an ongoing need for substantial capital to fund its research and development activities and clinical trials. The company's ability to raise additional capital, potentially through equity offerings, is crucial for its continued operations and advancement of its pipeline, and failure to do so could jeopardize its business.
AI Analysis | Feedback
null
AI Analysis | Feedback
Addressable Markets for Coya Therapeutics' Main Products and Services
Coya Therapeutics, Inc. is developing therapeutic modalities targeting several significant disease areas. The addressable markets for their main product candidates are outlined below:- COYA 101 (Amyotrophic Lateral Sclerosis - ALS): The global Amyotrophic Lateral Sclerosis (ALS) market was valued at approximately USD 0.79 billion in 2024 and is projected to reach USD 1.38 billion by 2035, growing at a Compound Annual Growth Rate (CAGR) of 5.2%. In North America, the ALS market is expected to hold the highest share, partly due to advanced healthcare infrastructure and increasing research and development activities. Another report indicates the global ALS market size was USD 835.8 million in 2025 and is projected to reach USD 1496.9 million by 2035. The market size for ALS in the United States was USD 800 million in 2024.
- COYA 301 (Frontotemporal Dementia - FTD): The market for Frontotemporal Dementia (FTD) across the 7 major markets (US, EU4 (Germany, Spain, Italy, and France), UK, and Japan) was valued at USD 142.8 million in 2024. This market is expected to reach USD 688.2 million by 2035, exhibiting a CAGR of 15.37% during the period 2025-2035. The United States accounted for the highest market size within the 7MM for FTD, with approximately USD 68 million in 2023. The global frontotemporal dementia market is also projected to increase from $3.25 billion in 2025 to $4.99 billion by 2030, at a CAGR of 9.0%.
- COYA 302 (Neurodegenerative and autoimmune diseases):
- Neurodegenerative Diseases: The global neurodegenerative disease market size was estimated at USD 52.3 billion in 2024 and is projected to grow to USD 81.23 billion in 2029 with a CAGR of 9.2%. Another estimate places the global neurodegenerative disease market size at approximately USD 61.93 billion in 2024, projected to reach USD 121.30 billion by 2034. North America was the largest region in the neurodegenerative disease market in 2024.
- Autoimmune Diseases: The global autoimmune disease therapeutics market is valued at USD 168.6 billion in 2025 and is forecast to reach USD 226.2 billion by 2035, reflecting a CAGR of 3.0%. The global Autoimmune Diseases Treatment market size was approximately $109.53 billion by the end of 2025. North America's Autoimmune Diseases Treatment market is dominant, with the United States holding a significant share.
- COYA 201 (Neurodegenerative, autoimmune, and metabolic diseases):
- Neurodegenerative Diseases: (See COYA 302 above)
- Autoimmune Diseases: (See COYA 302 above)
- Metabolic Diseases: The global metabolic disorder therapeutics market was valued at USD 74.97 billion in 2024 and is projected to reach USD 157.65 billion by 2033, growing at a CAGR of 8.6%. North America holds the largest revenue share in the global metabolic disorder therapeutics market.
- COYA 206 (Antigen directed Treg-derived exosome product candidate): Null
AI Analysis | Feedback
Coya Therapeutics (COYA) is a clinical-stage biotechnology company developing therapies to modulate regulatory T cells (Tregs) for neurodegenerative and autoimmune diseases. Over the next 2-3 years, the company's revenue growth is expected to be driven primarily by advancements in its clinical pipeline and strategic partnerships. Here are 3-5 expected drivers of future revenue growth for Coya Therapeutics:-
Milestone Payments from COYA 302 for ALS
A significant driver of near-term revenue growth for Coya Therapeutics is anticipated to come from milestone payments associated with its strategic partnership with Dr. Reddy's Laboratories. The FDA's acceptance of the Investigational New Drug (IND) application for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) has already triggered a $4.2 million milestone payment. An additional $4.2 million milestone payment is expected upon the first patient dosing in the COYA 302 ALSTARS trial for ALS. Dr. Reddy's Laboratories holds commercialization rights for COYA 302 in the U.S., U.K., Canada, and the European Union, positioning future product sales as a long-term revenue source if approved.
-
Advancement of COYA 302 into and through Phase 2 Clinical Trials for ALS
The progression of COYA 302 through its Phase 2 clinical trial for ALS, known as the ALSTARS trial, is a crucial revenue driver. The trial was launched in Q3 2025 and has expanded to include sites in Canada. Positive topline data from this Phase 2 study, anticipated in 2026, would significantly de-risk the asset and potentially lead to further strategic collaborations, increased investment, or more favorable terms in existing partnerships, ultimately paving the way for eventual commercialization and product revenue.
-
Progression of COYA 302 into Phase 2b Clinical Trials for Frontotemporal Dementia (FTD)
The planned submission of an IND for a Phase 2b study of COYA 302 in patients with Frontotemporal Dementia (FTD) represents another potential revenue growth driver. The company has already secured a $5.0 million strategic investment from the Alzheimer's Drug Discovery Foundation (ADDF) to support the development of COYA 302 for FTD. Successful advancement of COYA 302 in FTD could unlock additional funding, milestone payments, or partnership opportunities, broadening Coya's therapeutic reach and future revenue streams.
AI Analysis | Feedback
Share Issuance
- Coya Therapeutics closed its initial public offering (IPO) in January 2023, issuing 3,050,000 shares of common stock and accompanying warrants for gross proceeds of approximately $15.25 million.
- In October 2024, the company issued 1,379,314 shares of common stock in a private placement to accredited investors.
- Coya Therapeutics announced an $11.1 million private placement in January 2026.
Inbound Investments
- Dr. Reddy's Laboratories Ltd. (via a subsidiary) acquired a 9.7% stake in Coya Therapeutics in March 2026.
- Coya has received milestone payments from Dr. Reddy's Laboratories Ltd. under a Development and License Agreement, specifically tied to FDA acceptance of an Investigational New Drug (IND) application for COYA 302.
Capital Expenditures
- Capital expenditures have been reported as not available ("N/A") in recent financial summaries.
- The company's primary focus for capital allocation is to advance its programs in preclinical studies into clinical trials, further discovery and candidate selection stage programs, and for general corporate purposes.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Coya Therapeutics Earnings Notes | 12/16/2025 | |
| Is Coya Therapeutics Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to COYA.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.74 |
| Mkt Cap | 0.4 |
| Rev LTM | 2 |
| Op Inc LTM | -155 |
| FCF LTM | -122 |
| FCF 3Y Avg | -89 |
| CFO LTM | -121 |
| CFO 3Y Avg | -88 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -68.7% |
| Rev Chg 3Y Avg | -0.9% |
| Rev Chg Q | -7.1% |
| QoQ Delta Rev Chg LTM | 49.1% |
| Op Mgn LTM | -516.7% |
| Op Mgn 3Y Avg | -162.4% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | -304.5% |
| CFO/Rev 3Y Avg | -204.2% |
| FCF/Rev LTM | -304.5% |
| FCF/Rev 3Y Avg | -206.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.4 |
| P/S | 11.5 |
| P/EBIT | -2.2 |
| P/E | -2.2 |
| P/CFO | -2.6 |
| Total Yield | -32.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -24.3% |
| D/E | 0.0 |
| Net D/E | -0.4 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.0% |
| 3M Rtn | 5.5% |
| 6M Rtn | 22.7% |
| 12M Rtn | 62.9% |
| 3Y Rtn | -60.2% |
| 1M Excs Rtn | 8.4% |
| 3M Excs Rtn | 9.2% |
| 6M Excs Rtn | 17.2% |
| 12M Excs Rtn | 31.9% |
| 3Y Excs Rtn | -133.2% |
Price Behavior
| Market Price | $4.53 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 12/29/2022 | |
| Distance from 52W High | -38.5% | |
| 50 Days | 200 Days | |
| DMA Price | $4.81 | $5.71 |
| DMA Trend | down | down |
| Distance from DMA | -5.9% | -20.7% |
| 3M | 1YR | |
| Volatility | 59.2% | 65.4% |
| Downside Capture | 154.55 | 97.04 |
| Upside Capture | -17.13 | 40.87 |
| Correlation (SPY) | 21.1% | 26.3% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.89 | 0.77 | 0.84 | 0.49 | 0.91 | 0.90 |
| Up Beta | 5.36 | 5.47 | 4.34 | 2.13 | 0.82 | 0.93 |
| Down Beta | 2.94 | -0.31 | -0.08 | 0.83 | 1.36 | 1.11 |
| Up Capture | 306% | -56% | -54% | -39% | 31% | 41% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 17 | 26 | 55 | 113 | 349 |
| Down Capture | 130% | 41% | 116% | 31% | 91% | 93% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 9 | 22 | 33 | 65 | 130 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COYA | |
|---|---|---|---|---|
| COYA | -32.8% | 65.4% | -0.35 | - |
| Sector ETF (XLV) | 5.0% | 17.5% | 0.12 | 32.6% |
| Equity (SPY) | 19.6% | 18.9% | 0.81 | 26.6% |
| Gold (GLD) | 71.9% | 26.3% | 2.05 | 6.1% |
| Commodities (DBC) | 19.3% | 17.3% | 0.89 | 11.9% |
| Real Estate (VNQ) | 6.2% | 16.3% | 0.19 | 23.9% |
| Bitcoin (BTCUSD) | -15.0% | 44.2% | -0.24 | 26.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COYA | |
|---|---|---|---|---|
| COYA | -0.5% | 70.4% | 0.28 | - |
| Sector ETF (XLV) | 7.5% | 14.5% | 0.33 | 20.2% |
| Equity (SPY) | 13.1% | 17.0% | 0.61 | 19.0% |
| Gold (GLD) | 24.1% | 17.3% | 1.14 | 1.3% |
| Commodities (DBC) | 11.2% | 19.0% | 0.47 | 4.7% |
| Real Estate (VNQ) | 4.8% | 18.8% | 0.16 | 18.6% |
| Bitcoin (BTCUSD) | 6.4% | 56.7% | 0.33 | 12.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with COYA | |
|---|---|---|---|---|
| COYA | -0.2% | 70.4% | 0.28 | - |
| Sector ETF (XLV) | 10.1% | 16.5% | 0.50 | 20.2% |
| Equity (SPY) | 14.5% | 17.9% | 0.70 | 19.0% |
| Gold (GLD) | 14.4% | 15.6% | 0.77 | 1.3% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 4.7% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 18.6% |
| Bitcoin (BTCUSD) | 67.5% | 66.8% | 1.07 | 12.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | 1.3% | 2.5% | 2.8% |
| 8/12/2025 | -0.3% | -2.3% | 2.6% |
| 3/18/2025 | -5.8% | -2.9% | -19.6% |
| 11/6/2024 | 7.7% | 7.6% | -11.3% |
| 8/12/2024 | -12.9% | -15.5% | -4.3% |
| 3/19/2024 | 2.1% | -10.1% | -16.4% |
| 11/8/2023 | -0.1% | -0.3% | 36.2% |
| 8/8/2023 | 1.3% | -8.2% | 11.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 2 | 5 |
| # Negative | 5 | 7 | 4 |
| Median Positive | 1.7% | 5.0% | 11.4% |
| Median Negative | -4.5% | -8.2% | -13.9% |
| Max Positive | 7.7% | 7.6% | 36.2% |
| Max Negative | -12.9% | -15.5% | -19.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/13/2025 | 10-Q |
| 12/31/2024 | 03/18/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/09/2024 | 10-Q |
| 12/31/2023 | 03/19/2024 | 10-K |
| 09/30/2023 | 11/08/2023 | 10-Q |
| 06/30/2023 | 08/08/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 12/30/2022 | 424B4 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.